

CANCER  
CHEMOTHERAPY  
CHALLENGES  
FOR  
THE FUTURE  
Vol. 4

十月廿二日



1  
G-346

# CANCER CHEMOTHERAPY: Organizing Chairman Challenges for the Future Volume 4

Proceedings of the Fourth Nagoya International Symposium  
on Cancer Treatment, Nagoya, Japan, October 11-13, 1988

**Editors:**

- Kiyoji Kimura**
- Kazuo Ota**
- Stephen K. Carter**
- Herbert M. Pinedo**



1989

Excerpta Medica, Amsterdam-Princeton-Hong Kong-Tokyo-Sydney

© 1989 Elsevier Science Publishers B.V. (Biomedical Division)

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher. Elsevier Science Publishers B.V., Biomedical Division, P. O. Box 1527, 1000 BM Amsterdam, The Netherlands.

No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, the Publisher recommends that independent verification of diagnoses and drug dosages should be made.

Special regulations for readers in the USA—This publication has been registered with the Copyright Clearance Center Inc. (CCC), 27 Congress Street, Salem, MA 01970, USA. Information can be obtained from the CCC about conditions under which photocopies of parts of this publication may be made in the USA. All other copyright questions, including photocopying outside the USA, should be referred to the copyright owner, Elsevier Science Publishers B.V., unless otherwise specified.

International Congress Series No. 904  
ISBN 0 444 81189 3

*Published by:*  
Elsevier Science Publishers B.V.  
(Biomedical Division)  
P. O. Box 211  
1000 AE Amsterdam  
The Netherlands

*Sole distributors for the USA and Canada:*  
Elsevier Science Publishing Company Inc.  
655 Avenue of the Americas  
New York, NY 10010  
USA

Printed in Japan

(Biomedical Division) **CANCER CHEMOTHERAPY:**  
**Challenges for the Future**

Volume 4

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher. Elsevier Science Publishers B.V., Biomedical Division, P. O. Box 177, 1000 BM Amsterdam, The Netherlands.

No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, the Publisher recommends that independent verification of diagnoses and drug dosages should be made.

Special regulations for readers in the USA—This publication has been registered with the Copyright Clearance Center Inc. (CCC), 27 Congress Street, Salem, MA 01970, USA. Information can be obtained from the CCC about conditions under which photocopies of parts of this publication may be made in the USA. All other copyright questions, including photocopying outside the USA, should be referred to the copyright owner, Elsevier Science Publishers B.V., unless otherwise specified.

International Congress Series No. 804  
ISBN 0-444-81182-3



Published by Elsevier Science Publishers B.V., Biomedical Division, P. O. Box 177, 1000 AE Amsterdam, The Netherlands.

Printed in Japan.



## Organizing Committee

### Chairman

Kiyoji Kimura (Nagoya Memorial Hospital &  
National Nagoya Hospital)

### Vice Chairman; Chairman, Executive Committee

Kazuo Ota (Aichi Cancer Center)

### Secretary General

Kazumasa Yamada (Nagoya University)

### Organizing Committee

Osahiko Abe (Keio University)  
Genshichiro Fujii (University of Tokyo)  
Setsuro Fujii (The Osaka Foundation for Promotion of  
Fundamental Medical Research)  
Hisashi Furue (Teikyo University)  
Nobu Hattori (Kanazawa University)  
Takao Hattori (Hiroshima University)  
Heizaburo Ichikawa (National Cancer Center)  
Kiyoshi Inokuchi (Saga Prefectural Hospital, Koseikan)  
Toshi Kato (Kurume University)  
Ikuro Kimura (Okayama University)  
Tatsuhei Kondo (Nagoya University)  
Tadao Niijima (University of Tokyo)  
Hisanobu Niitani (Nippon Medical School)  
Makoto Ogawa (Japanese Foundation for Cancer Research)  
Hidehiko Saito (Nagoya University)  
Tatsuo Saito (Japanese Foundation for Cancer Research)  
Tetsuo Taguchi (Osaka University)  
Shigeru Tsukagoshi (Japanese Foundation for Cancer Research)  
Ichiro Urushizaki (Sapporo Medical College)  
Akira Wakui (Tohoku University)

## Advisory Board

Mitchell P. Cybulski (Bristol-Myers K.K.)  
Susumu Hibino (National Nagoya Hospital)  
Tamaki Kajitani (Japanese Foundation for Cancer Research)  
Yoshiyuki Koyama (National Medical Center)  
Yoshio Sakurai (Japanese Foundation for Cancer Research)

### Overseas Advisers

Stephen K. Carter (Bristol-Myers Company)  
Minoru Takata (Bristol-Myers Company)

## Preface

The Fourth Nagoya International Symposium on Cancer Treatment was successfully held from October 11 to 13, 1988, attended by about 400 oncologists. The proceedings of this symposium form the basis of this volume.

The book is divided into three parts. The first section, "Arterial infusion chemotherapy," covers aspects of its principles, pharmacokinetics, and clinical trials. The value of using such regional chemotherapy compared to systemic chemotherapy in randomized trial was discussed. Disease-oriented strategies, including chemotherapy regimens and the efficacy in terms of response rate and survival were presented and considered.

The second section, "Chemotherapy—curable solid tumors," covers childhood solid tumors, testicular tumors, and ovarian cancer. Major advances have been made in the management of childhood solid tumors. These advances were documented and evaluated in terms of treatment regimens and cure rate. Testicular tumors represented another demonstration of how therapeutic advances can be effectively implemented through use of diagnostic innovations and cisplatin-based chemotherapy. Encouraging results were also presented in ovarian cancer through use of aggressive chemotherapy which produced long-term survivors.

The third section is "Development of new drugs and clinical drug development methodology." The clinical development of new drugs is accomplished through the methodology of clinical trials. Current guidelines for conducting phase I-III study were presented, with emphasis on efficacy end points of phase III such as objective response, disease-free survival, survival, and quality of life. Principal aspects of requirements of the US FDA for cancer drug approval were also presented.

The clinical evaluation of new drugs related to problems in research, patient care, and regulatory matters was also reported, and clinical and regulatory challenges, currently facing new cisplatin analogues such as carboplatin, and registration strategies utilized in Europe, Japan, and the USA were also discussed.

The series of Nagoya International Symposia on Cancer Treatment began in 1985. Although not meant to be comprehensive, the objective of the series is to upgrade concepts in therapeutic strategy and preclinical studies, and to introduce developments in the major classes of compounds, identify new directions, and provide some landmarks of current clinical progress. Not only should this volume provide a comprehensive treatise on the role of cancer chemotherapy, but it should also give a perspective on future developments. Our gratitude is extended to all those who participated in and supported this effort.

Kiyoji Kimura

# CONTENTS

K. Kawanishi

## I. ARTERIAL INFUSION CHEMOTHERAPY: PHARMACOKINETICS

Pharmacokinetic rationale for intrarterial therapy	1
A. M. Collins	1
Hepatic arterial chemotherapy and embolization with degradable starch microspheres	11
J. Dowling, M. Anderson, S. Ekberg	11
Pharmacokinetics of arterial infusion chemotherapy	23
Experimental studies on optimal therapeutic schedule of arterial infusion chemotherapy with 5-fluorouracil	23
J. Oh, M. Fujita, T. Yaguchi	23
Advantage of intrarterial infusion chemotherapy in the first circulation	29
T. Kakita, K. Kawanishi	29
Pharmacokinetics in arterial chemotherapy with and without angiotensin II-stimulation by short-acting $\alpha_1$ -antagonist	30
Y. Suzuki, S. Imazeki, H. Ohtsuki, M. Kameyama, S. Noguchi, O. Ishikawa, I. Furuta, T. Shibata, H. Wada, H. Nagano, H. Koyama, T. Iwazumi, Y. Haragawa	30
New tactics and basic mechanism of targeting chemotherapy in solid tumors	42
H. Maeda, Y. Matsunaga	42
Discussion	51

## II. ARTERIAL INFUSION CHEMOTHERAPY: CLINICAL TRIALS (LIVER)

Hepatic arterial chemotherapy of liver metastases from colorectal carcinoma	61
K. Kawanishi	61
Discussion	68
Isolated liver perfusion for disseminated colorectal metastases—long-term results	70
K. R. Aigner, H. Wehrli, G. de Torny	70
Discussion	76
Phase II study of 5FU/ADR/MMC combined hepatic arterial infusion for liver metastases from colon, breast, and gastric cancer, and randomized trial of IV vs IA therapy	78
T. Arai	78
Discussion	84
Long-term results in transcatheter arterial chemembolization for hepatocellular carcinoma: ten years' experience	89
K. Yamada, M. Zato, Y. Sato, S. Nishimura, S. Nishimura	89

Preface.....	v
--------------	---

*K. Kimura*

## I. ARTERIAL INFUSION CHEMOTHERAPY: PHARMACOKINETICS

Pharmacokinetic rationale for intraarterial therapy <i>J. M. Collins</i> .....	3
Hepatic arterial chemotherapy and embolization with degradable starch microspheres <i>L. Domellöf, M. Andersson, S. Eksborg</i> .....	11
Pharmacokinetics of arterial infusion chemotherapy Experimental studies on optimal therapeutic schedule of arterial infusion chemotherapy with 5-fluorouracil <i>J. Ota, M. Fujita, T. Taguchi</i> .....	23
Advantage of intraarterial infusion chemotherapy in the first circulation <i>T. Kakuta, K. Kimura</i> .....	29
Pharmacokinetics in arterial chemotherapy with and without angiotensin II—examination by short-lived <sup>81m</sup> Kr <i>Y. Sasaki, S. Imaoka, H. Ohigashi, M. Kameyama, S. Noguchi, O. Ishikawa, I. Fukuda, T. Shibata, H. Wada, H. Nagano, H. Koyama, T. Iwanaga, Y. Hasegawa</i> .....	36
New tactics and basic mechanism of targeting chemotherapy in solid tumors <i>H. Maeda, Y. Matsumura</i> .....	42
Discussion .....	51

## II. ARTERIAL INFUSION CHEMOTHERAPY: CLINICAL TRIALS (LIVER)

Hepatic arterial chemotherapy of liver metastases from colorectal carcinoma <i>N. Kemeny</i> .....	61
Discussion .....	68
Isolated liver perfusion for disseminated colorectal metastases—long-term results <i>K. R. Aigner, H. Walther, G. de Toma</i> .....	70
Discussion .....	76
Phase II study of 5FU/ADR/MMC combined hepatic arterial infusion for liver metastases from colon, breast, and gastric cancer, and randomized trial of IV vs IA therapy <i>Y. Arai</i> .....	78
Discussion .....	84
Long-term results in transcatheter arterial chemoembolization for hepatocellular carcinoma: ten years' experience <i>R. Yamada, M. Sato, Y. Shioyama, S. Nomura</i> .....	86



Discussion .....	93
Chemoembolization using iodized oil in the treatment of hepatocellular carcinoma <i>H. Nakamura, T. Hashimoto, M. Fujita, H. Oi, S. Sawada</i> .....	95
Discussion .....	104

### III. ARTERIAL INFUSION CHEMOTHERAPY: CLINICAL TRIALS (OTHERS)

Intraarterial chemotherapy in management of advanced cancers in head and neck and breast, gastric cancer, and advanced sarcomas in limbs <i>F. O. Stephens</i> .....	107
Perfusion chemotherapy for limb melanoma and sarcoma <i>E. T. Kremenz, J. H. Muchmore, C. M. Sutherland, R. D. Carter</i> .....	115
Intraarterial chemotherapy for head and neck cancer <i>Y. Inuyama</i> .....	133
Intraaortic infusion chemotherapy by MMC/5-FU with angiotensin II and sequential MTX/5-FU therapy for advanced gastric cancer <i>M. Kitamura, K. Arai, T. Yoshikawa, G. Kosaki</i> .....	139
Intraarterial chemotherapy for bladder cancer by insertion of catheter from inferior gluteal artery <i>R. Noguchi, N. Miyanaga, S. Kanoh, K. Koiso</i> .....	144
Multidisciplinary, intraarterial chemotherapy (IAC) for cervical cancer <i>K. Akiya, H. Sato, T. Azuma, K. Fujiwara</i> .....	150
Discussion .....	155

### KEYNOTE ADDRESS

Perspectives in solid tumor research <i>H. M. Pinedo, C. J. van Groeningen</i> .....	163
Questions on the keynote address .....	172

### IV. CHEMOTHERAPY FOR CURABLE SOLID TUMORS: CHILDHOOD SOLID TUMORS

Decline in US childhood cancer mortality and the future beyond cure <i>A. M. Mauer</i> .....	177
Curative chemotherapy in childhood solid tumors <i>N. Jaffe</i> .....	186
Neoadjuvant chemotherapy for osteosarcoma in children <i>K. Sasaki</i> .....	195

Improved curability and changing concepts in pediatric abdominal tumor surgery <i>H. Ohkawa, M. Kaneko, S. Sawaguchi</i> .....	200
The persistent challenge of neuroblastoma: Role of N-myc oncogene and prognosis <i>A. Nakagawara</i> .....	208
Multiple primary malignancies in childhood cancer patients in Japan <i>Y. Tsunematsu, S. Watanabe</i> .....	214
Discussion .....	220

## V. CHEMOTHERAPY FOR CURABLE SOLID TUMORS: TESTICULAR TUMORS

Disseminated testicular cancer—refining the cure <i>C. Nichols, L. Einhorn, S. Williams</i> .....	227
Treatment of testicular tumor with a new cisplatin derivative <i>N. Deguchi, H. Akaza, M. Hagiwara, T. Kawai, Y. Satomi, T. Matsuda, T. Miki, T. Ueda, T. Kotake, H. Tazaki, Y. Aso, T. Nijima, and the Carboplatin Study Group</i> .....	235
“COMPE” chemotherapy, consisting of vincristine, peplomycin, methotrexate, cisplatin, and etoposide, for testicular cancer <i>T. Yamauchi, T. Kawai</i> .....	241
Multidisciplinary treatment of advanced testicular cancer <i>T. Kotake, T. Miki</i> .....	248
Discussion .....	256

## VI. CHEMOTHERAPY FOR CURABLE SOLID TUMORS: OVARIAN CANCER

Chemotherapy of curable solid tumors: Ovarian carcinoma <i>R. C. Young, T. C. Hamilton, J. D. Nash, R. F. Ozols</i> .....	263
The effects of extended surgery and increase in dose of cisplatin on an advanced ovarian cancer <i>Y. Terashima</i> .....	273
Evaluation of chemotherapy and surgical procedure in the management of advanced ovarian cancer <i>M. Yakushiji, H. Nishimura, K. Hamaguchi</i> .....	282
Comparison of preoperative and postoperative chemotherapy in the treatment of advanced ovarian cancer <i>K. Hirabayashi</i> .....	287
Multivariate statistical analysis of prognostic factors in ovarian cancer <i>M. Ohta</i> .....	293
Discussion .....	299

## VII. DEVELOPMENT OF NEW DRUGS: CAMPTOTHECINS

DNA topoisomerase poisons as antitumor drugs <i>Y.-H. Hsiang, L. F. Liu</i> .....	305
Antileukemic effects of CPT-11 (a new derivative of camptothecin) on rat leukemias and the isolation of resistant human leukemic cells <i>K. Okada, A. Mizutani, Y. Kusunoki, Y. Takemoto, A. Kuramoto</i> .....	312
Camptothecin-resistant mutant of human T-cells possessing altered DNA topoisomerase I <i>T. Andoh, K. Ishii</i> .....	317
Basic problems in combination cancer chemotherapy mainly consisting of antineoplastic agents with DNA-topoisomerase (topo) inhibitory action <i>M. Oguro</i> .....	321
Experimental and clinical studies on CPT-11 (a new derivative of camptothecin) <i>T. Taguchi, H. Furue, A. Wakui, H. Niitani, K. Ota, T. Hattori</i> .....	325
Discussion .....	328

## VIII. DEVELOPMENT OF NEW DRUGS: CLINICAL DRUG DEVELOPMENT METHODOLOGY

Cancer clinical trials <b>methodology</b> <i>J. R. Johnson</i> .....	335
New drug development—a clinical and regulation challenge <i>S. K. Carter, R. Canetta</i> .....	343
The clinical evaluation of new drugs: The phase II study <i>K. Yamada</i> .....	351
Discussion .....	355
<b>Closing remarks</b> <i>H. Saito</i> .....	363
<b>Author index</b> .....	369

**I. ARTERIAL INFUSION CHEMOTHERAPY:  
PHARMACOKINETICS**

I. ARTERIAL INFUSION CHEMOTHERAPY:  
PHARMACOKINETICS



# Pharmacokinetic rationale for intraarterial therapy

Jerry M. Collins

Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland, USA

## INTRODUCTION

Since all anticancer drugs have narrow therapeutic windows, it is natural to search for ways to specifically direct the effects of these drugs to the tumor rather than sensitive normal tissues. Intraarterial therapy provides one such approach to drug targeting. The primary goal of intraarterial therapy is to improve efficacy by producing selective changes in concentrations: to increase the concentration of drug delivered to tumors without raising the concentration of drug which is delivered to host tissues. In some circumstances, the strategic approach is to decrease host tissue concentrations without lowering tumor levels.

Although there is some tendency to try any drug in any disease area, pharmacologic principles can be used to select the most promising drugs and infusion sites. From a practical viewpoint, careful calculations can save years of clinical effort. Ideally, pharmacologic principles can focus resources into high-probability areas. Pharmacokinetic analysis can provide a rationale for intraarterial delivery, but a final evaluation of the utility of intraarterial therapy also requires consideration of the steepness of the dose-response curve and the rigorous challenge of controlled clinical trials.

This paper will describe the theoretical basis for such decision-making and give a specific example.

## INCREASED DELIVERY OF DRUG TO THE TUMOR

The ability of intraarterial delivery to increase drug levels at the tumor site will be considered first. This is a comparative evaluation, relative to drug delivery via the intravenous route. Thus, the increased delivery to the tumor can be defined:

$$R_{\text{tumor}} = C_{\text{tumor}(i.a.)} / C_{\text{tumor}(i.v.)} \quad [1]$$

Equation [1] is a general definition of the pharmacokinetic advantage of intraarterial delivery which can be used to evaluate experimental results.

The next step in this analysis is to use pharmacokinetic modeling to develop

formulas which can be used to calculate  $R_{\text{tumor}}$  for various intraarterial situations.

Figure 1 illustrates our conceptual approach to the modeling of intraarterial drug delivery. If there is no elimination of drug by the organ being perfused, then  $R_{\text{tumor}}$  can be readily calculated. For the same dose of drug given intraarterially and intravenously,  $R_{\text{tumor}}$  is the ratio of tumor concentrations:

$$R_{\text{tumor}} = \frac{C_{\text{tumor}}(\text{i.a.})}{C_{\text{tumor}}(\text{i.v.})} = 1 + \frac{CL_{\text{TB}}}{Q} \quad [2]$$

$CL_{\text{TB}}$  is total body clearance of the drug, which can be found in the literature or determined from intravenous doses.  $Q$  is blood flow in the infused artery.

The ratio of  $CL_{\text{TB}}$  to  $Q$  is the sole determinant of drug delivery advantage.

At first, it is appealing to assume that the rate of drug transfer across capillaries is an important factor for selection of compounds for intraarterial testing. However, since the evaluation of the drug delivery advantage for the intraarterial route is relative to systemic delivery, both routes share the same ease or difficulty of transcapillary passage.

Although first-pass extraction of a drug can be a useful property for increasing the advantage of arterial delivery (see next section), there is no absolute requirement for any first-pass effect. If the same dose is delivered intravenously or intraarterially, then Equation [2] describes the ratio of tumor concentrations regardless of the presence or absence of a first-pass extraction.




Figure 1. Schematic diagram for intraarterial infusion without a first-pass effect. Reprinted from Collins (1), with permission.

One of the conditions for Equation [2] is that the comparison between intraarterial and intravenous routes is based upon equal doses. This implies that the limiting host tissue is outside the site of direct infusion. If toxicity to local tissues is limiting, then intraarterial delivery of the same dose is not possible and the actual value for  $R_{\text{tumor}}$  will be lowered.

The drug delivery advantage can be calculated before doing an experiment or clinical study. Such calculations should influence the selection of drugs (based upon  $CL_{\text{TB}}$ ) and infusion sites (based upon  $Q$ ). As shown in Table 1, some drugs have such high  $CL_{\text{TB}}$  that they remain attractive regardless of the blood flow. Also, some drugs have such low  $CL_{\text{TB}}$  that they are not attractive candidates for any artery. However, the majority of agents fall in the middle area, so that a drug may be attractive in a low-flow situation, but not in a high-flow area.

TABLE 1

INTRAARTERIAL DRUG DELIVERY ADVANTAGE,  $R_{\text{tumor}}$

Examples for selected anticancer drugs at high-flow ( $Q=1000$  ml/min) or low-flow ( $Q=100$  ml/min). Based upon Equation [2].

CL <sub>TB</sub> ml/min	DRUG	$R_{\text{tumor}}$	
		Q=100 ml/min	Q=1000 ml/min
25000	Fluorodeoxyuridine	251	26
5000	Teroxirone	51	6
4000	Fluorouracil	41	5
3000	Cytosine Arabinoside	31	4
2500	Bromodeoxyuridine	26	3.5
1300	Iododeoxyuridine	14	2.3
1000	Carmustine	11	2
900	Doxorubicin	10	1.9
400	Diaziquone	5	1.4
400	Cisplatin	5	1.4
200	Methotrexate	3	1.2
40	Etoposide	1.4	1.04
--*	Cyclophosphamide	1	1

\* Drugs which must be activated at a site other than the arterial infusion site have no drug delivery advantage.

## FIRST-PASS EFFECTS: ELIMINATION OF DRUG BY THE PERFUSED ORGAN

If a certain fraction,  $E$ , of the infused dose is eliminated by the perfused organ (such as the liver), then  $1-E$  is available to the systemic circulation. For equal doses:

$$R_{\text{systemic}} = \frac{C_{\text{systemic}}(i.a.)}{C_{\text{systemic}}(i.v.)} = 1 - E \quad [3]$$

If acute systemic toxicity is dose-limiting, a larger dose can be given intraarterially than intravenously. If cumulative systemic toxicity is dose-limiting, then a larger number of doses (or a longer infusion) can be given intraarterially.

The overall pharmacokinetic advantage of intraarterial administration,  $R_d$  is composed of the increased local concentration and/or the decreased systemic concentration:

$$R_d = \frac{R_{\text{tumor}}}{R_{\text{systemic}}} = \frac{C_{\text{tumor}}(i.a.) / C_{\text{tumor}}(i.v.)}{C_{\text{systemic}}(i.a.) / C_{\text{systemic}}(i.v.)} \quad [4]$$

If  $E=0$ ,  $R_{\text{systemic}}=1$  and  $R_d = R_{\text{tumor}}$ . When  $E \neq 0$ ,  $R_{\text{systemic}}$  is less than 1, which generally increases the overall value of  $R_d$ . However, in some cases,  $R_{\text{tumor}}$  is adversely lowered by local extraction. In fact,  $R_{\text{tumor}}$  can be reduced to 1 if the perfused organ is the sole site of drug elimination from the body.

The liver is frequently the principal organ of drug elimination. The anatomy of hepatic blood supply provides several options for intravascular drug delivery and for pre-systemic drug elimination. There can be differences for perfusion via the hepatic artery vs. the portal vein, particularly for large tumors (2). More specific details for the calculation of  $R_d$  for a variety of situations are presented elsewhere (3).

Some experimental studies have shown that the hepatic arterial route is superior to the portal venous route for delivery of drug to established (large) tumors. For small (micro) metastases in the liver, drug delivery via the portal route is probably as effective as via the hepatic artery.

## MODIFIED APPROACHES TO INTRAARTERIAL DELIVERY

In order to maximize the drug delivery advantage, "superselective" catheterization is sometimes utilized, that is, the catheter is placed as close to the tumor site as possible. In pharmacokinetic terms (Equation [2]), this procedure increases the value of  $R_{\text{tumor}}$ , since the smaller the artery, the lower the blood flow.